# Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

> **NCT03287414** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** VAY736
- **DRUG:** Placebo
- **DRUG:** Standard of Care (SoC)

## Key facts

- **NCT ID:** NCT03287414
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-20
- **Primary completion:** 2020-11-25
- **Final completion:** 2022-02-14
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03287414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03287414, "Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03287414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*